LXRX ▼ -0.7% - Lexicon Pharmaceuticals, Inc.
$LXRX - Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
23-OCT-2026 08:30 AM ET
Share this post
More filings for $LXRX
LXRX ▼ -0.6% - Lexicon Pharmaceuticals, Inc.Oct 21, 2026LXRX ▼ -2.2% - Lexicon Pharmaceuticals, Inc.Sep 1, 2026LXRX ▲ +0.4% - Lexicon Pharmaceuticals, Inc.Aug 31, 2026LXRX - Lexicon Pharmaceuticals, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026
View full $LXRX filing history →💬 Comments
Loading comments…
Leave a comment